Skip to main content

Table 2 Univariate and multivariate Cox regression analysis of overall survival of the two cohorts

From: B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

  Univariate Multivariate
HR 95%CI P HR 95%CI P
Training cohort
 Age(continuous) 1.006 0.986 ~  1.025 0.574 1.004 0.985 ~  1.024 0.661
 Gender(male vs female) 0.697 0.383 ~  1.268 0.240    
 B4GALT1(high vs low) 1.849 1.126 ~  3.035 0.016 1.773 1.075 ~  2.924 0.026
 CCI(≥2 vs ≤1) 1.154 0.712 ~  1.872 0.563    
 LVI(present vs absent) 1.449 0.898 ~  2.339 0.131    
 pN(N+ vs N-) 1.651 0.718 ~  3.795 0.240    
 pT stage
  pT3 vs pT2 1.063 0.625 ~  1.808 0.824    
  pT4 vs pT2 1.765 1.005 ~  3.100 0.049    
 TNM stage
  III vs II 1.278 0.797 ~  2.051 0.312 1.220 0.759 ~  1.961 0.414
  IV vs II 1.877 0.784 ~  4.492 0.159 1.636 0.680 ~  3.938 0.274
Validation cohort
 Age(continuous) 1.062 1.020 ~  1.105 0.004 1.050 1.006 ~  1.095 0.025
 Gender(male vs female) 0.929 0.369 ~  2.337 0.876    
 B4GALT1(high vs low) 2.158 1.187 ~  3.923 0.012 1.862 1.016 ~  3.413 0.046
 CCI(≥2 vs ≤1) 1.847 0.993 ~  3.438 0.054    
 LVI(present vs absent) 1.926 1.073 ~  3.456 0.029 1.060 0.458 ~  2.452 0.893
 pN(N+ vs N-) 1.626 1.194 ~  2.213 0.002    
 pT stage
  pT3 vs pT2 2.708 1.426 ~  5.142 0.003    
  pT4 vs pT2 2.517 0.967 ~  6.550 0.060    
 TNM stage
  III vs II 3.291 1.471 ~  7.362 0.004 2.555 1.126 ~  5.796 0.026
  IV vs II 6.290 2.874 ~  13.768 < 0.001 5.230 1.962 ~  13.943 0.001